4.3 Article

The effect of low-molecular-weight heparin on immune balance of patients with repeated implantation failure during the implantation window

Journal

CELLULAR AND MOLECULAR BIOLOGY
Volume 69, Issue 4, Pages 112-115

Publisher

C M B ASSOC
DOI: 10.14715/cmb/2023.69.4.17

Keywords

Immune balance; implantation window; low molecular weight heparin; repeated implantation failure

Ask authors/readers for more resources

This study investigates the effect of low-molecular-weight heparin (LMWH) on cytokines in patients with repeated implantation failure. The results suggest that LMWH treatment during the implantation window can improve the immune imbalance by inhibiting Th1 cytokines and enhancing Th2 cytokines, making it a potential treatment strategy for patients with abnormal cellular immunity.
This study investigates the effect of low-molecular-weight heparin (LMWH) on cytokines TNF-& alpha;, IFN-& gamma;, IL-2, IL-4, IL-6, and IL-10 in peripheral blood of patients with repeated implantation failure during the implantation window. From May 2019 to March 2021, we enrolled 32 patients with recurrent implantation failure (RIF group) and 30 patients with successful pregnancy after the first frozen embryo transfer (control group) in the Reproductive Medicine Centre of Wuxi Maternity and Child Health Care Hospital. During the implantation window, the following features were compared between two groups and between different time points using ELISA: the status of immune cytokines in peripheral blood; Th1 cytokines (TNF-& alpha;, IFN-& gamma;, and IL-2) and Th2 cytokines (IL-4, IL-6, and IL-10) in peripheral blood. The levels of Th1 cytokines in the RIF group before treatment were higher in comparison with the control group. In the RIF group, the LMWH treatment can inhibit the expression of Th1 cytokines and enhance the expression of Th2 cytokines. Using LMWH during the implantation window can improve the immune imbalance of patients with repeated implantation failure, which makes it a potential treatment strategy for patients with abnormal cellular immunity. Copyright: & COPY; 2023 by the C.M.B. Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available